BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease

@article{Baro2016BACE1PF,
  title={BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease},
  author={Soraia Bar{\~a}o and Diederik W. Moechars and Stefan F. Lichtenthaler and Bart de Strooper},
  journal={Trends in Neurosciences},
  year={2016},
  volume={39},
  pages={158-169}
}
The protease β-site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1) is required for the production of the amyloid-β (Aβ) peptide, which is central to the pathogenesis of Alzheimer's disease (AD). Chronic inhibition of this protease may temper amyloid production and cure or prevent AD. However, while BACE1 inhibitors are being pushed forward as drug candidates, a remarkable gap in knowledge on the physiological functions of BACE1 and its close homolog BACE2 becomes apparent. Here we… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 3 times. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations